<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1991-08-01" modified="2018-01-31" version="200">
<accession>P22455</accession>
<accession>G3JVM2</accession>
<accession>G3JVM5</accession>
<accession>G3JVM7</accession>
<accession>G3JVM9</accession>
<accession>O43785</accession>
<accession>Q14309</accession>
<accession>Q71TW8</accession>
<accession>Q8TDA0</accession>
<accession>Q96KE5</accession>
<name>FGFR4_HUMAN</name>
<protein>
<recommendedName>
<fullName>Fibroblast growth factor receptor 4</fullName>
<shortName>FGFR-4</shortName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<cdAntigenName>CD334</cdAntigenName>
</protein>
<gene>
<name type="primary">FGFR4</name>
<name type="synonym">JTK2</name>
<name type="synonym">TKF</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="EMBO J." volume="10" first="1347" last="1354">
<title>FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern.</title>
<authorList>
<person name="Partanen J.M."/>
<person name="Maekelae T.P."/>
<person name="Eerola E."/>
<person name="Korhonen J."/>
<person name="Hirvonen H."/>
<person name="Claesson-Welsh L."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="1709094"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1993" name="J. Biol. Chem." volume="268" first="5388" last="5394">
<title>Fibroblast growth factor receptor 4 is a high affinity receptor for both acidic and basic fibroblast growth factor but not for keratinocyte growth factor.</title>
<authorList>
<person name="Ron D."/>
<person name="Reich R."/>
<person name="Chedid M."/>
<person name="Lengel C."/>
<person name="Cohen O.E."/>
<person name="Chan A.M."/>
<person name="Neufeld G."/>
<person name="Miki T."/>
<person name="Tronick S.R."/>
</authorList>
<dbReference type="PubMed" id="7680645"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>FUNCTION AS RECEPTOR FOR FGF1 AND FGF2</scope>
<source>
<tissue>Mammary gland</tissue>
</source>
</reference>
<reference key="3">
<citation type="journal article" date="2000" name="Biochem. Biophys. Res. Commun." volume="267" first="658" last="662">
<title>Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells.</title>
<authorList>
<person name="Takaishi S."/>
<person name="Sawada M."/>
<person name="Morita Y."/>
<person name="Seno H."/>
<person name="Fukuzawa H."/>
<person name="Chiba T."/>
</authorList>
<dbReference type="PubMed" id="10631118"/>
<dbReference type="DOI" id="10.1006/bbrc.1999.2010"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<scope>VARIANT LEU-136</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
<source>
<tissue>Intestine</tissue>
</source>
</reference>
<reference key="4">
<citation type="journal article" date="1998" name="Mamm. Genome" volume="9" first="131" last="135">
<title>Genomic structure and complete sequence of the human FGFR4 gene.</title>
<authorList>
<person name="Kostrzewa M."/>
<person name="Muller U."/>
</authorList>
<dbReference type="PubMed" id="9457674"/>
<dbReference type="DOI" id="10.1007/s003359900703"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2002" name="J. Clin. Invest." volume="109" first="69" last="78">
<title>Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.</title>
<authorList>
<person name="Ezzat S."/>
<person name="Zheng L."/>
<person name="Zhu X.F."/>
<person name="Wu G.E."/>
<person name="Asa S.L."/>
</authorList>
<dbReference type="PubMed" id="11781352"/>
<dbReference type="DOI" id="10.1172/JCI14036"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
<scope>SUBCELLULAR LOCATION (ISOFORM 3)</scope>
<scope>INVOLVEMENT IN CANCER</scope>
<scope>VARIANT PC ARG-388</scope>
<source>
<tissue>Pituitary</tissue>
</source>
</reference>
<reference key="6">
<citation type="journal article" date="2012" name="Mol. Carcinog." volume="51" first="807" last="815">
<title>PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.</title>
<authorList>
<person name="Marshall A.D."/>
<person name="van der Ent M.A."/>
<person name="Grosveld G.C."/>
</authorList>
<dbReference type="PubMed" id="21882254"/>
<dbReference type="DOI" id="10.1002/mc.20848"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>VARIANTS ILE-10 AND LEU-136</scope>
<scope>INVOLVEMENT IN CANCER</scope>
<scope>VARIANT PC ARG-388</scope>
</reference>
<reference key="7">
<citation type="submission" date="2002-02" db="EMBL/GenBank/DDBJ databases">
<title>Sequence variation in fibroblast growth factor receptors 3 and 4.</title>
<authorList>
<person name="Lind D.L."/>
<person name="Cox D.R."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANT LEU-136</scope>
</reference>
<reference key="8">
<citation type="submission" date="2007-04" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS ILE-10; LEU-136 AND ARG-388</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2004" name="Nature" volume="431" first="268" last="274">
<title>The DNA sequence and comparative analysis of human chromosome 5.</title>
<authorList>
<person name="Schmutz J."/>
<person name="Martin J."/>
<person name="Terry A."/>
<person name="Couronne O."/>
<person name="Grimwood J."/>
<person name="Lowry S."/>
<person name="Gordon L.A."/>
<person name="Scott D."/>
<person name="Xie G."/>
<person name="Huang W."/>
<person name="Hellsten U."/>
<person name="Tran-Gyamfi M."/>
<person name="She X."/>
<person name="Prabhakar S."/>
<person name="Aerts A."/>
<person name="Altherr M."/>
<person name="Bajorek E."/>
<person name="Black S."/>
<person name="Branscomb E."/>
<person name="Caoile C."/>
<person name="Challacombe J.F."/>
<person name="Chan Y.M."/>
<person name="Denys M."/>
<person name="Detter J.C."/>
<person name="Escobar J."/>
<person name="Flowers D."/>
<person name="Fotopulos D."/>
<person name="Glavina T."/>
<person name="Gomez M."/>
<person name="Gonzales E."/>
<person name="Goodstein D."/>
<person name="Grigoriev I."/>
<person name="Groza M."/>
<person name="Hammon N."/>
<person name="Hawkins T."/>
<person name="Haydu L."/>
<person name="Israni S."/>
<person name="Jett J."/>
<person name="Kadner K."/>
<person name="Kimball H."/>
<person name="Kobayashi A."/>
<person name="Lopez F."/>
<person name="Lou Y."/>
<person name="Martinez D."/>
<person name="Medina C."/>
<person name="Morgan J."/>
<person name="Nandkeshwar R."/>
<person name="Noonan J.P."/>
<person name="Pitluck S."/>
<person name="Pollard M."/>
<person name="Predki P."/>
<person name="Priest J."/>
<person name="Ramirez L."/>
<person name="Retterer J."/>
<person name="Rodriguez A."/>
<person name="Rogers S."/>
<person name="Salamov A."/>
<person name="Salazar A."/>
<person name="Thayer N."/>
<person name="Tice H."/>
<person name="Tsai M."/>
<person name="Ustaszewska A."/>
<person name="Vo N."/>
<person name="Wheeler J."/>
<person name="Wu K."/>
<person name="Yang J."/>
<person name="Dickson M."/>
<person name="Cheng J.-F."/>
<person name="Eichler E.E."/>
<person name="Olsen A."/>
<person name="Pennacchio L.A."/>
<person name="Rokhsar D.S."/>
<person name="Richardson P."/>
<person name="Lucas S.M."/>
<person name="Myers R.M."/>
<person name="Rubin E.M."/>
</authorList>
<dbReference type="PubMed" id="15372022"/>
<dbReference type="DOI" id="10.1038/nature02919"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="10">
<citation type="submission" date="2005-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
<scope>VARIANT LEU-136</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Muscle</tissue>
</source>
</reference>
<reference key="12">
<citation type="journal article" date="1990" name="Proc. Natl. Acad. Sci. U.S.A." volume="87" first="8913" last="8917">
<title>Putative tyrosine kinases expressed in K-562 human leukemia cells.</title>
<authorList>
<person name="Partanen J."/>
<person name="Maekelae T.P."/>
<person name="Alitalo R."/>
<person name="Lehvaeslaiho H."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="2247464"/>
<dbReference type="DOI" id="10.1073/pnas.87.22.8913"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 609-676</scope>
<source>
<tissue>Blood</tissue>
</source>
</reference>
<reference key="13">
<citation type="journal article" date="2004" name="Protein Sci." volume="13" first="2819" last="2824">
<title>Signal peptide prediction based on analysis of experimentally verified cleavage sites.</title>
<authorList>
<person name="Zhang Z."/>
<person name="Henzel W.J."/>
</authorList>
<dbReference type="PubMed" id="15340161"/>
<dbReference type="DOI" id="10.1110/ps.04682504"/>
</citation>
<scope>PROTEIN SEQUENCE OF 22-38</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="18320" last="18326">
<title>Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1.</title>
<authorList>
<person name="Vainikka S."/>
<person name="Joukov V."/>
<person name="Wennstrom S."/>
<person name="Bergman M."/>
<person name="Pelicci P.G."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="7518429"/>
</citation>
<scope>FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND PIK3R1</scope>
<scope>INTERACTION WITH PLCG1</scope>
<scope>PHOSPHORYLATION AT TYR-754</scope>
<scope>MUTAGENESIS OF TYR-754</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="15292" last="15297">
<title>Receptor specificity of the fibroblast growth factor family.</title>
<authorList>
<person name="Ornitz D.M."/>
<person name="Xu J."/>
<person name="Colvin J.S."/>
<person name="McEwen D.G."/>
<person name="MacArthur C.A."/>
<person name="Coulier F."/>
<person name="Gao G."/>
<person name="Goldfarb M."/>
</authorList>
<dbReference type="PubMed" id="8663044"/>
<dbReference type="DOI" id="10.1074/jbc.271.25.15292"/>
</citation>
<scope>INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9</scope>
<scope>FUNCTION IN CELL PROLIFERATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2001" name="Nat. Cell Biol." volume="3" first="650" last="657">
<title>N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling.</title>
<authorList>
<person name="Cavallaro U."/>
<person name="Niedermeyer J."/>
<person name="Fuxa M."/>
<person name="Christofori G."/>
</authorList>
<dbReference type="PubMed" id="11433297"/>
<dbReference type="DOI" id="10.1038/35083041"/>
</citation>
<scope>FUNCTION IN CELL DIFFERENTIATION</scope>
<scope>MUTAGENESIS OF LYS-503</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1; FRS2; SRC; SHC; GAP43 AND CTTN</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2002" name="Cancer Res." volume="62" first="840" last="847">
<title>Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.</title>
<authorList>
<person name="Bange J."/>
<person name="Prechtl D."/>
<person name="Cheburkin Y."/>
<person name="Specht K."/>
<person name="Harbeck N."/>
<person name="Schmitt M."/>
<person name="Knyazeva T."/>
<person name="Mueller S."/>
<person name="Gaertner S."/>
<person name="Sures I."/>
<person name="Wang H."/>
<person name="Imyanitov E."/>
<person name="Haering H.U."/>
<person name="Knayzev P."/>
<person name="Iacobelli S."/>
<person name="Hoefler H."/>
<person name="Ullrich A."/>
</authorList>
<dbReference type="PubMed" id="11830541"/>
</citation>
<scope>INVOLVEMENT IN CANCER</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="15694" last="15700">
<title>Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.</title>
<authorList>
<person name="Zhang X."/>
<person name="Ibrahimi O.A."/>
<person name="Olsen S.K."/>
<person name="Umemori H."/>
<person name="Mohammadi M."/>
<person name="Ornitz D.M."/>
</authorList>
<dbReference type="PubMed" id="16597617"/>
<dbReference type="DOI" id="10.1074/jbc.M601252200"/>
</citation>
<scope>INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23</scope>
<scope>FUNCTION IN STIMULATION OF CELL PROLIFERATION</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="26687" last="26695">
<title>Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.</title>
<authorList>
<person name="Kurosu H."/>
<person name="Choi M."/>
<person name="Ogawa Y."/>
<person name="Dickson A.S."/>
<person name="Goetz R."/>
<person name="Eliseenkova A.V."/>
<person name="Mohammadi M."/>
<person name="Rosenblatt K.P."/>
<person name="Kliewer S.A."/>
<person name="Kuro-o M."/>
</authorList>
<dbReference type="PubMed" id="17623664"/>
<dbReference type="DOI" id="10.1074/jbc.M704165200"/>
</citation>
<scope>INTERACTION WITH FGF19; FGF21 AND KLB</scope>
<scope>FUNCTION IN SIGNALING AND IN REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2007" name="J. Cell. Physiol." volume="212" first="148" last="156">
<title>Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus.</title>
<authorList>
<person name="Citores L."/>
<person name="Bai L."/>
<person name="Sorensen V."/>
<person name="Olsnes S."/>
</authorList>
<dbReference type="PubMed" id="17311277"/>
<dbReference type="DOI" id="10.1002/jcp.21014"/>
</citation>
<scope>FUNCTION IN STAT1 PHOSPHORYLATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>MUTAGENESIS OF LYS-503</scope>
<scope>GLYCOSYLATION</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2008" name="Int. J. Cancer" volume="123" first="2574" last="2579">
<title>Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.</title>
<authorList>
<person name="Ma Z."/>
<person name="Tsuchiya N."/>
<person name="Yuasa T."/>
<person name="Inoue T."/>
<person name="Kumazawa T."/>
<person name="Narita S."/>
<person name="Horikawa Y."/>
<person name="Tsuruta H."/>
<person name="Obara T."/>
<person name="Saito M."/>
<person name="Satoh S."/>
<person name="Ogawa O."/>
<person name="Habuchi T."/>
</authorList>
<dbReference type="PubMed" id="18756523"/>
<dbReference type="DOI" id="10.1002/ijc.23578"/>
</citation>
<scope>INVOLVEMENT IN PC</scope>
<scope>VARIANT PC ARG-388</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2008" name="Mol. Biol. Cell" volume="19" first="3390" last="3403">
<title>Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis.</title>
<authorList>
<person name="Haugsten E.M."/>
<person name="Malecki J."/>
<person name="Bjorklund S.M."/>
<person name="Olsnes S."/>
<person name="Wesche J."/>
</authorList>
<dbReference type="PubMed" id="18480409"/>
<dbReference type="DOI" id="10.1091/mbc.E07-12-1219"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF PLCG1; FRS2; MAPK1/ERK2 AND MAPK3/ERK1</scope>
<scope>ENZYME REGULATION</scope>
<scope>UBIQUITINATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2008" name="Neoplasia" volume="10" first="847" last="856">
<title>Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.</title>
<authorList>
<person name="Wang J."/>
<person name="Yu W."/>
<person name="Cai Y."/>
<person name="Ren C."/>
<person name="Ittmann M.M."/>
</authorList>
<dbReference type="PubMed" id="18670643"/>
<dbReference type="DOI" id="10.1593/neo.08450"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF CELL PROLIFERATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH FGF2 AND HIP1</scope>
<scope>PHOSPHORYLATION AT TYR-642 AND TYR-643</scope>
<scope>INVOLVEMENT IN PC</scope>
<scope>CHARACTERIZATION OF VARIANT PC ARG-388</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2010" name="Eur. J. Cancer" volume="46" first="3332" last="3338">
<title>FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.</title>
<authorList>
<person name="Xu W."/>
<person name="Li Y."/>
<person name="Wang X."/>
<person name="Chen B."/>
<person name="Wang Y."/>
<person name="Liu S."/>
<person name="Xu J."/>
<person name="Zhao W."/>
<person name="Wu J."/>
</authorList>
<dbReference type="PubMed" id="20638838"/>
<dbReference type="DOI" id="10.1016/j.ejca.2010.06.017"/>
</citation>
<scope>INVOLVEMENT IN CANCER</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2010" name="Hepatology" volume="52" first="656" last="666">
<title>Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.</title>
<authorList>
<person name="Triantis V."/>
<person name="Saeland E."/>
<person name="Bijl N."/>
<person name="Oude-Elferink R.P."/>
<person name="Jansen P.L."/>
</authorList>
<dbReference type="PubMed" id="20683963"/>
<dbReference type="DOI" id="10.1002/hep.23708"/>
</citation>
<scope>FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS VIA CYP7A1</scope>
<scope>INTERACTION WITH FGF19; KL AND KLB</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>GLYCOSYLATION</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2010" name="J. Biol. Chem." volume="285" first="5165" last="5170">
<title>FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.</title>
<authorList>
<person name="Wu X."/>
<person name="Ge H."/>
<person name="Lemon B."/>
<person name="Vonderfecht S."/>
<person name="Weiszmann J."/>
<person name="Hecht R."/>
<person name="Gupte J."/>
<person name="Hager T."/>
<person name="Wang Z."/>
<person name="Lindberg R."/>
<person name="Li Y."/>
</authorList>
<dbReference type="PubMed" id="20018895"/>
<dbReference type="DOI" id="10.1074/jbc.M109.068783"/>
</citation>
<scope>FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2010" name="Proc. Natl. Acad. Sci. U.S.A." volume="107" first="15786" last="15791">
<title>FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex.</title>
<authorList>
<person name="Sugiyama N."/>
<person name="Varjosalo M."/>
<person name="Meller P."/>
<person name="Lohi J."/>
<person name="Chan K.M."/>
<person name="Zhou Z."/>
<person name="Alitalo K."/>
<person name="Taipale J."/>
<person name="Keski-Oja J."/>
<person name="Lehti K."/>
</authorList>
<dbReference type="PubMed" id="20798051"/>
<dbReference type="DOI" id="10.1073/pnas.0914459107"/>
</citation>
<scope>FUNCTION IN DOWN-REGULATION OF MMP14</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>INTERACTION WITH MMP14</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2011" name="BMC Cancer" volume="11" first="84" last="84">
<title>FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.</title>
<authorList>
<person name="Xu B."/>
<person name="Tong N."/>
<person name="Chen S.Q."/>
<person name="Hua L.X."/>
<person name="Wang Z.J."/>
<person name="Zhang Z.D."/>
<person name="Chen M."/>
</authorList>
<dbReference type="PubMed" id="21349172"/>
<dbReference type="DOI" id="10.1186/1471-2407-11-84"/>
</citation>
<scope>INVOLVEMENT IN PC</scope>
<scope>VARIANT PC ARG-388</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2011" name="Eur. J. Cancer Prev." volume="20" first="340" last="347">
<title>Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.</title>
<authorList>
<person name="Frullanti E."/>
<person name="Berking C."/>
<person name="Harbeck N."/>
<person name="Jezequel P."/>
<person name="Haugen A."/>
<person name="Mawrin C."/>
<person name="Parise O. Jr."/>
<person name="Sasaki H."/>
<person name="Tsuchiya N."/>
<person name="Dragani T.A."/>
</authorList>
<dbReference type="PubMed" id="21412156"/>
<dbReference type="DOI" id="10.1097/CEJ.0b013e3283457274"/>
</citation>
<scope>INVOLVEMENT IN CANCER</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="26418" last="26423">
<title>Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.</title>
<authorList>
<person name="Nakamura M."/>
<person name="Uehara Y."/>
<person name="Asada M."/>
<person name="Honda E."/>
<person name="Nagai N."/>
<person name="Kimata K."/>
<person name="Suzuki M."/>
<person name="Imamura T."/>
</authorList>
<dbReference type="PubMed" id="21653700"/>
<dbReference type="DOI" id="10.1074/jbc.M111.251140"/>
</citation>
<scope>FUNCTION IN FGF19 SIGNALING</scope>
<scope>FUNCTION IN STIMULATION OF CELL PROLIFERATION AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1</scope>
<scope>INTERACTION WITH FGF19; KLB AND SULFATED GLYCOSAMINOGLYCANS</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="33">
<citation type="journal article" date="2014" name="J. Proteomics" volume="96" first="253" last="262">
<title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.</title>
<authorList>
<person name="Bian Y."/>
<person name="Song C."/>
<person name="Cheng K."/>
<person name="Dong M."/>
<person name="Wang F."/>
<person name="Huang J."/>
<person name="Sun D."/>
<person name="Wang L."/>
<person name="Ye M."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="24275569"/>
<dbReference type="DOI" id="10.1016/j.jprot.2013.11.014"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="34">
<citation type="journal article" date="2015" name="Nature" volume="528" first="570" last="574">
<title>Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.</title>
<authorList>
<person name="Ulaganathan V.K."/>
<person name="Sperl B."/>
<person name="Rapp U.R."/>
<person name="Ullrich A."/>
</authorList>
<dbReference type="PubMed" id="26675719"/>
<dbReference type="DOI" id="10.1038/nature16449"/>
</citation>
<scope>INTERACTION WITH STAT3</scope>
<scope>INVOLVEMENT IN CANCER</scope>
<scope>CHARACTERIZATION OF VARIANT PC ARG-388</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426; ASN-516; MET-550; THR-712 AND ASN-772</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2005" name="Cytokine Growth Factor Rev." volume="16" first="139" last="149">
<title>Cellular signaling by fibroblast growth factor receptors.</title>
<authorList>
<person name="Eswarakumar V.P."/>
<person name="Lax I."/>
<person name="Schlessinger J."/>
</authorList>
<dbReference type="PubMed" id="15863030"/>
<dbReference type="DOI" id="10.1016/j.cytogfr.2005.01.001"/>
</citation>
<scope>REVIEW ON LIGAND SELECTIVITY AND SIGNALING</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2010" name="Nat. Rev. Cancer" volume="10" first="116" last="129">
<title>Fibroblast growth factor signalling: from development to cancer.</title>
<authorList>
<person name="Turner N."/>
<person name="Grose R."/>
</authorList>
<dbReference type="PubMed" id="20094046"/>
<dbReference type="DOI" id="10.1038/nrc2780"/>
</citation>
<scope>REVIEW ON FUNCTION IN FGF SIGNALING</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2010" name="Cancer Res." volume="70" first="7851" last="7861">
<title>Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.</title>
<authorList>
<person name="Sugiyama N."/>
<person name="Varjosalo M."/>
<person name="Meller P."/>
<person name="Lohi J."/>
<person name="Hyytiainen M."/>
<person name="Kilpinen S."/>
<person name="Kallioniemi O."/>
<person name="Ingvarsen S."/>
<person name="Engelholm L.H."/>
<person name="Taipale J."/>
<person name="Alitalo K."/>
<person name="Keski-Oja J."/>
<person name="Lehti K."/>
</authorList>
<dbReference type="PubMed" id="20876804"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-10-1223"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT PC ARG-388</scope>
<scope>FUNCTION IN TUMOR CELL INVASION</scope>
</reference>
<comment type="function">
<text evidence="15 19 20 22 23 24 26 28 29 30 33 36 37 38">Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.</text>
</comment>
<comment type="catalytic activity">
<text evidence="13 15 20 23 24">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="23">Present in an inactive conformation in the absence of bound ligand. Ligand binding leads to dimerization and activation by autophosphorylation on tyrosine residues.</text>
</comment>
<comment type="subunit">
<text evidence="15 19 22 24 28 29 33 35 36 38">Monomer. Homodimer after ligand binding. Interacts with FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19, FGF21 and FGF23 (in vitro). Binding affinity for FGF family members is enhanced by interactions between FGFs and heparan sulfate proteoglycans. Interacts with KLB; this strongly increases the affinity for FGF19 and FGF23. Affinity for FGF19 is strongly increased by KLB and sulfated glycosaminoglycans. KLB and KL both interact with the core-glycosylated FGFR4 in the endoplasmic reticulum and promote its degradation, so that only FGFR4 with fully mature N-glycans is expressed at the cell surface. Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Interacts with MMP14 and HIP1 (PubMed:11433297, PubMed:16597617, PubMed:17623664, PubMed:18670643, PubMed:20683963, PubMed:20798051, PubMed:21653700, PubMed:7518429, PubMed:8663044). Interacts with STAT3 (PubMed:26675719).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-6256193"/>
<interactant intactId="EBI-992788">
<id>P50281</id>
<label>MMP14</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location>Endosome</location>
</subcellularLocation>
<subcellularLocation>
<location>Endoplasmic reticulum</location>
</subcellularLocation>
<text>Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 2</molecule>
<subcellularLocation>
<location>Secreted</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 3</molecule>
<subcellularLocation>
<location evidence="16">Cytoplasm</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P22455-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P22455-2</id>
<name>2</name>
<name>Soluble-form</name>
<sequence type="described" ref="VSP_035108"/>
</isoform>
<isoform>
<id>P22455-3</id>
<name>3</name>
<sequence type="described" ref="VSP_053542"/>
<text>Lacks a signal peptide. Constitutively phosphorylated.</text>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="14">Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines.</text>
</comment>
<comment type="PTM">
<text>N-glycosylated. Full maturation of the glycan chains in the Golgi is essential for high affinity interaction with FGF19.</text>
</comment>
<comment type="PTM">
<text evidence="23">Ubiquitinated. Subject to proteasomal degradation when not fully glycosylated.</text>
</comment>
<comment type="PTM">
<text evidence="20 24 36">Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer.</text>
</comment>
<comment type="disease" evidence="24 25 30 31">
<disease id="DI-02663">
<name>Prostate cancer</name>
<acronym>PC</acronym>
<description>A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.</description>
<dbReference type="MIM" id="176807"/>
</disease>
<text evidence="16 17 24 25 27 30 31 32 34 35">The gene represented in this entry is involved in disease pathogenesis. FGFR4 variant Arg-388 has been associated with prostate cancer as well as cancers of the breast, colon, head and neck, larynx, lung, skin. Arg-388 predisposes cancer patients for accelerated disease progression and is associated with poor prognosis.</text>
</comment>
<comment type="similarity">
<text evidence="12">Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.</text>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/fgfr4/"/>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/FGFR4ID512ch5q35.html"/>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="X57205">
<property type="protein sequence ID" value="CAA40490.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L03840">
<property type="protein sequence ID" value="AAB59389.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF202063">
<property type="protein sequence ID" value="AAF27432.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="Y13901">
<property type="protein sequence ID" value="CAA74200.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF359246">
<property type="protein sequence ID" value="AAK51435.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007471">
<property type="protein sequence ID" value="AEO19712.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007472">
<property type="protein sequence ID" value="AEO19713.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007473">
<property type="protein sequence ID" value="AEO19714.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007474">
<property type="protein sequence ID" value="AEO19715.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007475">
<property type="protein sequence ID" value="AEO19716.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007476">
<property type="protein sequence ID" value="AEO19717.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007477">
<property type="protein sequence ID" value="AEO19718.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007478">
<property type="protein sequence ID" value="AEO19719.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007479">
<property type="protein sequence ID" value="AEO19720.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007480">
<property type="protein sequence ID" value="AEO19721.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007481">
<property type="protein sequence ID" value="AEO19722.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="JN007482">
<property type="protein sequence ID" value="AEO19723.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF487555">
<property type="protein sequence ID" value="AAM13666.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="EF571596">
<property type="protein sequence ID" value="ABQ01235.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC027314">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471195">
<property type="protein sequence ID" value="EAW85036.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC011847">
<property type="protein sequence ID" value="AAH11847.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M59373">
<property type="protein sequence ID" value="AAA63208.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS4410.1">
<molecule id="P22455-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS4411.1">
<molecule id="P22455-2"/>
</dbReference>
<dbReference type="PIR" id="S15345">
<property type="entry name" value="TVHUF4"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001278909.1">
<property type="nucleotide sequence ID" value="NM_001291980.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_002002.3">
<molecule id="P22455-1"/>
<property type="nucleotide sequence ID" value="NM_002011.4"/>
</dbReference>
<dbReference type="RefSeq" id="NP_075252.2">
<molecule id="P22455-2"/>
<property type="nucleotide sequence ID" value="NM_022963.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_998812.1">
<molecule id="P22455-1"/>
<property type="nucleotide sequence ID" value="NM_213647.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_005265895.1">
<property type="nucleotide sequence ID" value="XM_005265838.3"/>
</dbReference>
<dbReference type="UniGene" id="Hs.165950"/>
<dbReference type="PDB" id="1QCT">
<property type="method" value="Model"/>
<property type="chains" value="B/E=36-353"/>
</dbReference>
<dbReference type="PDB" id="4QQ5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDB" id="4QQC">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDB" id="4QQJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.68"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDB" id="4QQT">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.50"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDB" id="4QRC">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDB" id="4R6V">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.35"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDB" id="4TYE">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A=447-753"/>
</dbReference>
<dbReference type="PDB" id="4TYG">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=447-753"/>
</dbReference>
<dbReference type="PDB" id="4TYI">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.40"/>
<property type="chains" value="A=447-753"/>
</dbReference>
<dbReference type="PDB" id="4TYJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.45"/>
<property type="chains" value="A=447-753"/>
</dbReference>
<dbReference type="PDB" id="4UXQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A=447-753"/>
</dbReference>
<dbReference type="PDB" id="4XCU">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.71"/>
<property type="chains" value="A=449-751"/>
</dbReference>
<dbReference type="PDB" id="5JKG">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.35"/>
<property type="chains" value="A=445-753"/>
</dbReference>
<dbReference type="PDBsum" id="1QCT"/>
<dbReference type="PDBsum" id="4QQ5"/>
<dbReference type="PDBsum" id="4QQC"/>
<dbReference type="PDBsum" id="4QQJ"/>
<dbReference type="PDBsum" id="4QQT"/>
<dbReference type="PDBsum" id="4QRC"/>
<dbReference type="PDBsum" id="4R6V"/>
<dbReference type="PDBsum" id="4TYE"/>
<dbReference type="PDBsum" id="4TYG"/>
<dbReference type="PDBsum" id="4TYI"/>
<dbReference type="PDBsum" id="4TYJ"/>
<dbReference type="PDBsum" id="4UXQ"/>
<dbReference type="PDBsum" id="4XCU"/>
<dbReference type="PDBsum" id="5JKG"/>
<dbReference type="ProteinModelPortal" id="P22455"/>
<dbReference type="SMR" id="P22455"/>
<dbReference type="BioGrid" id="108555">
<property type="interactions" value="37"/>
</dbReference>
<dbReference type="CORUM" id="P22455"/>
<dbReference type="DIP" id="DIP-5149N"/>
<dbReference type="IntAct" id="P22455">
<property type="interactions" value="25"/>
</dbReference>
<dbReference type="STRING" id="9606.ENSP00000292408"/>
<dbReference type="BindingDB" id="P22455"/>
<dbReference type="ChEMBL" id="CHEMBL3973"/>
<dbReference type="DrugBank" id="DB09078">
<property type="generic name" value="Lenvatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00039">
<property type="generic name" value="Palifermin"/>
</dbReference>
<dbReference type="DrugBank" id="DB08901">
<property type="generic name" value="Ponatinib"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1811"/>
<dbReference type="TCDB" id="8.A.23.1.9">
<property type="family name" value="the basigin (basigin) family"/>
</dbReference>
<dbReference type="iPTMnet" id="P22455"/>
<dbReference type="PhosphoSitePlus" id="P22455"/>
<dbReference type="BioMuta" id="FGFR4"/>
<dbReference type="DMDM" id="13432140"/>
<dbReference type="EPD" id="P22455"/>
<dbReference type="MaxQB" id="P22455"/>
<dbReference type="PaxDb" id="P22455"/>
<dbReference type="PeptideAtlas" id="P22455"/>
<dbReference type="PRIDE" id="P22455"/>
<dbReference type="DNASU" id="2264"/>
<dbReference type="Ensembl" id="ENST00000292408">
<molecule id="P22455-1"/>
<property type="protein sequence ID" value="ENSP00000292408"/>
<property type="gene ID" value="ENSG00000160867"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000393637">
<molecule id="P22455-2"/>
<property type="protein sequence ID" value="ENSP00000377254"/>
<property type="gene ID" value="ENSG00000160867"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000502906">
<molecule id="P22455-1"/>
<property type="protein sequence ID" value="ENSP00000424960"/>
<property type="gene ID" value="ENSG00000160867"/>
</dbReference>
<dbReference type="GeneID" id="2264"/>
<dbReference type="KEGG" id="hsa:2264"/>
<dbReference type="UCSC" id="uc003mfl.4">
<molecule id="P22455-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="2264"/>
<dbReference type="DisGeNET" id="2264"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000160867.14"/>
<dbReference type="GeneCards" id="FGFR4"/>
<dbReference type="HGNC" id="HGNC:3691">
<property type="gene designation" value="FGFR4"/>
</dbReference>
<dbReference type="HPA" id="CAB005196"/>
<dbReference type="HPA" id="HPA027273"/>
<dbReference type="HPA" id="HPA027369"/>
<dbReference type="HPA" id="HPA028251"/>
<dbReference type="MalaCards" id="FGFR4"/>
<dbReference type="MIM" id="134935">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="176807">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P22455"/>
<dbReference type="OpenTargets" id="ENSG00000160867"/>
<dbReference type="PharmGKB" id="PA28130"/>
<dbReference type="eggNOG" id="KOG0200">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118923"/>
<dbReference type="HOGENOM" id="HOG000263410"/>
<dbReference type="HOVERGEN" id="HBG000345"/>
<dbReference type="InParanoid" id="P22455"/>
<dbReference type="KO" id="K05095"/>
<dbReference type="OMA" id="THPQRME"/>
<dbReference type="OrthoDB" id="EOG091G0CQZ"/>
<dbReference type="PhylomeDB" id="P22455"/>
<dbReference type="TreeFam" id="TF316307"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-109704">
<property type="pathway name" value="PI3K Cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1257604">
<property type="pathway name" value="PIP3 activates AKT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1307965">
<property type="pathway name" value="betaKlotho-mediated ligand binding"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1839128">
<property type="pathway name" value="FGFR4 mutant receptor activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-190322">
<property type="pathway name" value="FGFR4 ligand binding and activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2219530">
<property type="pathway name" value="Constitutive Signaling by Aberrant PI3K in Cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654228">
<property type="pathway name" value="Phospholipase C-mediated cascade, FGFR4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654712">
<property type="pathway name" value="FRS-mediated FGFR4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654719">
<property type="pathway name" value="SHC-mediated cascade:FGFR4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654720">
<property type="pathway name" value="PI-3K cascade:FGFR4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654733">
<property type="pathway name" value="Negative regulation of FGFR4 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5655291">
<property type="pathway name" value="Signaling by FGFR4 in disease"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5673001">
<property type="pathway name" value="RAF/MAP kinase cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6811558">
<property type="pathway name" value="PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"/>
</dbReference>
<dbReference type="SIGNOR" id="P22455"/>
<dbReference type="ChiTaRS" id="FGFR4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="GeneWiki" id="Fibroblast_growth_factor_receptor_4"/>
<dbReference type="GenomeRNAi" id="2264"/>
<dbReference type="PRO" id="PR:P22455"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 5"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000160867"/>
<dbReference type="CleanEx" id="HS_FGFR4"/>
<dbReference type="ExpressionAtlas" id="P22455">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P22455">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005768">
<property type="term" value="C:endosome"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005576">
<property type="term" value="C:extracellular region"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030133">
<property type="term" value="C:transport vesicle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016303">
<property type="term" value="F:1-phosphatidylinositol-3-kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0017134">
<property type="term" value="F:fibroblast growth factor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005007">
<property type="term" value="F:fibroblast growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008201">
<property type="term" value="F:heparin binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046934">
<property type="term" value="F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0004713">
<property type="term" value="F:protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005088">
<property type="term" value="F:Ras guanyl-nucleotide exchange factor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0016477">
<property type="term" value="P:cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008543">
<property type="term" value="P:fibroblast growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042593">
<property type="term" value="P:glucose homeostasis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0000165">
<property type="term" value="P:MAPK cascade"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0055062">
<property type="term" value="P:phosphate ion homeostasis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043085">
<property type="term" value="P:positive regulation of catalytic activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000573">
<property type="term" value="P:positive regulation of DNA biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070374">
<property type="term" value="P:positive regulation of ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010628">
<property type="term" value="P:positive regulation of gene expression"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051897">
<property type="term" value="P:positive regulation of protein kinase B signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0045862">
<property type="term" value="P:positive regulation of proteolysis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070857">
<property type="term" value="P:regulation of bile acid biosynthetic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000188">
<property type="term" value="P:regulation of cholesterol homeostasis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010715">
<property type="term" value="P:regulation of extracellular matrix disassembly"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019216">
<property type="term" value="P:regulation of lipid metabolic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="InterPro" id="IPR016248">
<property type="entry name" value="FGF_rcpt_fam"/>
</dbReference>
<dbReference type="InterPro" id="IPR007110">
<property type="entry name" value="Ig-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR036179">
<property type="entry name" value="Ig-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR013098">
<property type="entry name" value="Ig_I-set"/>
</dbReference>
<dbReference type="InterPro" id="IPR003599">
<property type="entry name" value="Ig_sub"/>
</dbReference>
<dbReference type="InterPro" id="IPR003598">
<property type="entry name" value="Ig_sub2"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="Pfam" id="PF07679">
<property type="entry name" value="I-set"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF000628">
<property type="entry name" value="FGFR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00109">
<property type="entry name" value="TYRKINASE"/>
</dbReference>
<dbReference type="SMART" id="SM00409">
<property type="entry name" value="IG"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00408">
<property type="entry name" value="IGc2"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48726">
<property type="entry name" value="SSF48726"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50835">
<property type="entry name" value="IG_LIKE"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0967">Endosome</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0393">Immunoglobulin domain</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0964">Secreted</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="signal peptide" evidence="18">
<location>
<begin position="1"/>
<end position="21"/>
</location>
</feature>
<feature type="chain" description="Fibroblast growth factor receptor 4" id="PRO_0000016787">
<location>
<begin position="22"/>
<end position="802"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="10">
<location>
<begin position="22"/>
<end position="369"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="10">
<location>
<begin position="370"/>
<end position="390"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="10">
<location>
<begin position="391"/>
<end position="802"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 1">
<location>
<begin position="22"/>
<end position="118"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 2">
<location>
<begin position="152"/>
<end position="240"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 3">
<location>
<begin position="249"/>
<end position="349"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="12">
<location>
<begin position="467"/>
<end position="755"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="12">
<location>
<begin position="473"/>
<end position="481"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="12 13">
<location>
<position position="612"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="12">
<location>
<position position="503"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8 9">
<location>
<position position="573"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="24">
<location>
<position position="642"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="24">
<location>
<position position="643"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="36">
<location>
<position position="754"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="10">
<location>
<position position="112"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="10">
<location>
<position position="258"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="10">
<location>
<position position="290"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="10">
<location>
<position position="311"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="10">
<location>
<position position="322"/>
</location>
</feature>
<feature type="disulfide bond" evidence="11">
<location>
<begin position="57"/>
<end position="101"/>
</location>
</feature>
<feature type="disulfide bond" evidence="11">
<location>
<begin position="172"/>
<end position="224"/>
</location>
</feature>
<feature type="disulfide bond" evidence="11">
<location>
<begin position="271"/>
<end position="333"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_053542" evidence="43">
<location>
<begin position="1"/>
<end position="210"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_035108" evidence="42">
<original>EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLAR</original>
<variation>GTGRIPHLTCDSLTPAGRTKSPTL</variation>
<location>
<begin position="353"/>
<end position="416"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1966265." id="VAR_029185" evidence="21 34 41">
<original>V</original>
<variation>I</variation>
<location>
<position position="10"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs376618." id="VAR_042211" evidence="14 21 34 39 40 41">
<original>P</original>
<variation>L</variation>
<location>
<position position="136"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55675160." id="VAR_042212" evidence="21">
<original>T</original>
<variation>A</variation>
<location>
<position position="179"/>
</location>
</feature>
<feature type="sequence variant" description="In PC; also found in other types of cancer; associated with increased disease susceptibility, accelerated cancer progression and poor prognosis; results in prolonged FGFR4 activity; causes increased cell motility and tumor cell invasion possibly due to increased stability of the protease MMP14; increased interaction with STAT3; results in STAT3 phosphorylation and signaling activation; dbSNP:rs351855." id="VAR_014797" evidence="16 24 25 30 31 34 35 41">
<original>G</original>
<variation>R</variation>
<location>
<position position="388"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55879131." id="VAR_046102" evidence="21">
<original>G</original>
<variation>S</variation>
<location>
<position position="426"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34158682." id="VAR_042213" evidence="21">
<original>D</original>
<variation>N</variation>
<location>
<position position="516"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34284947." id="VAR_049720">
<original>R</original>
<variation>Q</variation>
<location>
<position position="529"/>
</location>
</feature>
<feature type="sequence variant" description="In breast pleomorphic lobular sample; somatic mutation; dbSNP:rs774571806." id="VAR_046103" evidence="21">
<original>V</original>
<variation>M</variation>
<location>
<position position="550"/>
</location>
</feature>
<feature type="sequence variant" description="In a lung adenocarcinoma sample; somatic mutation." id="VAR_046104" evidence="21">
<original>P</original>
<variation>T</variation>
<location>
<position position="712"/>
</location>
</feature>
<feature type="sequence variant" description="In a lung neuroendocrine carcinoma sample; somatic mutation." id="VAR_046105" evidence="21">
<original>S</original>
<variation>N</variation>
<location>
<position position="772"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of kinase activity." evidence="15 20">
<original>K</original>
<variation>R</variation>
<location>
<position position="503"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of interaction with PLCG1." evidence="36">
<original>Y</original>
<variation>F</variation>
<location>
<position position="754"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; AAF27432." ref="3" evidence="44">
<original>L</original>
<variation>S</variation>
<location>
<position position="121"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; AAF27432." ref="3" evidence="44">
<original>E</original>
<variation>G</variation>
<location>
<position position="194"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; CAA40490." ref="1" evidence="44">
<original>D</original>
<variation>V</variation>
<location>
<position position="297"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="445"/>
<end position="448"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="458"/>
<end position="460"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="464"/>
<end position="466"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="467"/>
<end position="474"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="480"/>
<end position="487"/>
</location>
</feature>
<feature type="strand" evidence="7">
<location>
<begin position="493"/>
<end position="495"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="497"/>
<end position="504"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="511"/>
<end position="527"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="536"/>
<end position="540"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="542"/>
<end position="544"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="547"/>
<end position="551"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="558"/>
<end position="563"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="572"/>
<end position="574"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="586"/>
<end position="605"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="615"/>
<end position="617"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="618"/>
<end position="620"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="626"/>
<end position="628"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="631"/>
<end position="635"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="637"/>
<end position="639"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="642"/>
<end position="644"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="652"/>
<end position="655"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="658"/>
<end position="663"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="668"/>
<end position="683"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="689"/>
<end position="692"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="695"/>
<end position="703"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="716"/>
<end position="725"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="730"/>
<end position="732"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="736"/>
<end position="748"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4QQ5"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4QQT"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4TYE"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4TYJ"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4UXQ"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4XCU"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5JKG"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="24275569"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000255"/>
<evidence key="11" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00114"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10631118"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11433297"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11781352"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11830541"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15340161"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16597617"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17311277"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17623664"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18480409"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18670643"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18756523"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20018895"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20638838"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20683963"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20798051"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20876804"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21349172"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21412156"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21653700"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21882254"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26675719"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7518429"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7680645"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8663044"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source ref="10"/>
</evidence>
<evidence key="40" type="ECO:0000269">
<source ref="7"/>
</evidence>
<evidence key="41" type="ECO:0000269">
<source ref="8"/>
</evidence>
<evidence key="42" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="10631118"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="11781352"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000305"/>
<sequence length="802" mass="87954" checksum="B22B259831BB889F" modified="2001-04-27" version="2" precursor="true">
MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRA
ERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDS
LTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTP
TIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLD
VLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFP
YVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTA
AAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSL
ESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQ
VVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVC
TQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGM
QYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEA
LFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYG
LMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDS
VFSHDPLPLGSSSFPFGSGVQT
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>